The decrease was primarily driven by fourth quarter cash used in operating activities of $19.5 million and partially offset by $18.4 million in net proceeds from sales of common stock under the Cantor agreement. At December 31, 2017, Celldex …
A year ago, they were trading at $3.46. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CLDX at https://www.zacks.com/ap/CLDX
Agenus ... Celldex's vaccine failure was one of 2016's worst: Rintega performed as expected, but the control group receiving standard chemo did unusually well. It looks like the heavy losses left bruises that the market isn't ready to …
Celldex Therapeutics, Inc. CLDX is expected to report third-quarter 2016 results on Nov 3. Celldex’s performance has been encouraging with a three-quarter average positive surprise of 4.85%. In the last reported quarter, the company recorded …
After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Celldex Therapeutics wasn't …
Celldex Therapeutics, Inc. CLDX is expected to report third-quarter 2016 results on Nov 3. Celldex’s performance has been encouraging with a three-quarter average positive surprise of 4.85%. In the last reported quarter, the company recorded …